NUK - logo
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • Blood Biomarkers of Respons...
    Alfranca, Yolanda Lage; Garcia, María Eugenia Olmedo; Rueda, Ana Gómez; Ballesteros, Pablo Álvarez; Rodríguez, Diana Rosero; Velasco, Marisa Torres

    Journal of clinical medicine, 06/2022, Letnik: 11, Številka: 11
    Journal Article

    Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of non-small cell lung cancer (NSCLC), either used in monotherapy or in combination with chemotherapy. While some patients achieve durable responses, some will not get benefit from this treatment. Early identification of non- responder patients could avoid unnecessary treatment, potentially serious immune-related adverse events and reduce treatment costs. PD-L1 expression using immunohistochemistry is the only approved biomarker for the selection of patients that can benefit from immunotherapy. However, application of PD-L1 as a biomarker of treatment efficacy shows many deficiencies probably due to the complexity of the tumor microenvironment and the technical limitations of the samples. Thus, there is an urgent need to find other biomarkers, ideally blood biomarkers to help us to identify different subgroups of patients in a minimal invasive way. In this review, we summarize the emerging blood-based markers that could help to predict the response to ICIs in NSCLC.